CIRM Funded Clinical Trials

A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases


Saul Priceman
Disease Area: 
Breast Cancer
Investigator:
CIRM Grant:
CLIN2-11574 (Pre-Active)
Award Value:
$9,288,375
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
39
ClinicalTrials.gov ID:
Details: 

Breast cancer is the second-most common cancer in women, both in the United States (US) and worldwide.  Some types of breast cancer have a high likelihood of metastasizing to the brain, meaning there are tumors in the brain that have spread from the original site of the breast cancer  When that happens, there are few treatment options, leading to a poor prognosis and poor quality of life. 

This clinical trial is testing a therapy to treat brain metastases that came from breast cancers expressing high levels of a protein called HER2.   The therapy consists of a genetically-modified version of the patient’s own T cells, which are an immune system cell that can destroy foreign or abnormal cells.  The T cells are modified with a protein called a chimeric antigen receptor (CAR) that recognizes the tumor protein HER2.  These modified T cells (CAR-T cells) are then infused into the patient’s brain where they are expected to detect and destroy the HER2-expressing tumors in the brain.

Design: 

This is a Phase I clinical trial. 

Goal: 

 To assess safety and to determine the recommended dose for delivery of HER2-CAR T cells.